The Coalition for Epidemic Preparedness Innovations (CEPI) has launched an urgent, multi-pronged initiative to develop a vaccine for the Bundibugyo ebolavirus (BDBV), an increasingly concerning pathogen currently affecting communities in the Democratic Republic of the Congo (DRC) and Uganda. As the virus spreads, the lack of any licensed vaccine or established clinical pipeline has prompted a global mobilization, with CEPI backing three distinct technological approaches led by IAVI, Moderna, and the University of Oxford.
This move marks a critical juncture in global health security. With only two previous documented outbreaks of BDBV in history, the virus has remained an "orphan" pathogen—deadly, yet lacking the commercial incentive for traditional pharmaceutical investment. By de-risking these programs, CEPI aims to bridge the gap between laboratory potential and real-world epidemic control.
Main Facts: A Tripartite Technological Assault
The effort to curb the BDBV epidemic is defined by its diversity of technological platforms, each chosen for its potential to provide rapid, durable immunity.
IAVI’s Recombinant Vesicular Stomatitis Virus (rVSV)
IAVI, utilizing technology originally pioneered at the University of Texas Medical Branch, is moving forward with an rVSV-based vaccine. This platform is a proven workhorse in the fight against filoviruses; it is the backbone of the only currently licensed Zaire ebolavirus vaccine and saw successful deployment during the 2025 Sudan virus outbreak in Uganda. The IAVI candidate is designed to elicit strong protective immunity from a single dose, an essential attribute for containing outbreaks in remote or resource-limited settings.
Moderna’s mRNA Innovation
Moderna is leveraging the same messenger RNA (mRNA) technology that propelled it to the forefront of the COVID-19 response. This candidate is the most ambitious in terms of scale, with CEPI committing up to $50 million to cover preclinical testing, Phase 1 clinical trials, and concurrent manufacturing. This "at-risk" manufacturing strategy is intended to allow for a seamless transition into Phase 2 and 3 trials, provided the initial safety data is positive.
The University of Oxford’s Viral Vector Platform
The University of Oxford is deploying its ChAdOx1 viral vector technology—the same platform that underpinned the AstraZeneca COVID-19 vaccine. This platform has already demonstrated robust efficacy against a range of filoviruses, including Zaire ebolavirus, the Sudan virus, and the Marburg virus. The $8.6 million investment from CEPI will focus on critical early-stage development, including the creation of a Master Virus Seed stock and the production of clinical-grade doses for human testing.
Chronology: From Outbreak to Accelerated Response
The trajectory of this crisis and the subsequent intervention can be mapped against a backdrop of increasing epidemiological pressure in East Africa.
- Early 2026: Reports of BDBV emergence in the DRC and Uganda trigger an immediate alert from the World Health Organization (WHO) and Africa CDC. The rapid, albeit localized, spread of the virus highlights the vulnerability of the region to this specific strain.
- April–May 2026: CEPI engages in an intensive global consultation process with public health authorities to identify the most viable vaccine candidates. The goal is to move beyond mere theoretical research and into actionable, trial-ready products.
- June 2026: CEPI officially announces the selection of the IAVI, Moderna, and Oxford candidates. This announcement coincides with the allocation of initial tranches of funding, signaling the shift from the assessment phase to the development phase.
- Mid-2026 and Beyond: The immediate focus shifts to the generation of Master Virus Seed stocks and the transfer of production protocols to Contract Development and Manufacturing Organizations (CDMOs). Subsequent timelines will depend on the speed of regulatory approval for Phase 1 human trials.
Supporting Data: The Economic and Scientific Landscape
The development of vaccines for rare, localized outbreaks is notoriously difficult. Without a guaranteed commercial market, private companies often shy away from the significant R&D costs required to bring a vaccine from the lab to the clinic.
Financial Realities for Industry
Moderna, while a leader in mRNA, has faced a challenging financial landscape. Following a 30% year-over-year revenue decline in Q4 2025 and a modest $0.4 billion revenue reported for Q1 2026, the company’s R&D spend—which hit $3.1 billion in 2025 against $1.9 billion in revenue—has come under intense scrutiny. CEPI’s $50 million investment acts as a vital subsidy, allowing Moderna to advance its filovirus pipeline without the prohibitive financial risk that would otherwise stall the project.
The Shifting U.S. Policy Environment
The initiative comes at a time of significant policy upheaval in the United States. In August 2025, the U.S. government took the controversial step of terminating 22 federal contracts specifically focused on mRNA vaccine development. By winding down these investments, the government effectively shifted the burden of innovation to private entities and international partnerships like CEPI. Consequently, the success of the BDBV program is now viewed as a bellwether for the future of mRNA research in the absence of broad federal support.
Comparative Efficacy and Readiness
The choice of candidates reflects a strategic balance between proven efficacy and experimental speed:
- rVSV (IAVI): Most promising for immediate, single-dose protection based on past outbreaks.
- mRNA (Moderna): Highest potential for rapid, scalable manufacturing if the platform is successfully adapted to BDBV.
- ChAdOx1 (Oxford): Offers a reliable, well-understood vector system with a strong track record of protecting against other filoviruses.
Official Responses and Strategic Intent
The urgency of this initiative was underscored by Richard Hatchett, CEO of CEPI, in a recent press statement. "With the Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease," Hatchett noted. He emphasized that the support for these three candidates is not just about scientific inquiry, but about "advancing safe, effective vaccines to help control this epidemic" as efficiently as possible.
Stephane Bancel, CEO of Moderna, echoed this sense of urgency, stating, "We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."
The coordination between CEPI, the WHO, and the Africa CDC represents a new model of global epidemic response—one that relies on decentralized manufacturing and synchronized regulatory pathways to overcome the limitations of traditional, linear drug development.
Implications: The Future of Global Health Preparedness
The decision to fast-track these three vaccines carries profound implications for the future of pandemic prevention and the management of "neglected" diseases.
1. Decoupling R&D from Commercial Profit
By providing non-dilutive funding to manufacturers, CEPI is proving that the pharmaceutical industry can be effectively leveraged to address health threats that would otherwise be ignored. This model—where international organizations de-risk the development process—is increasingly essential for diseases that appear in low-income, geographically isolated regions.
2. Validating New Platforms for Rare Pathogens
The success of these programs would serve as a "proof of concept" for the use of mRNA and viral vector platforms against rare, emerging pathogens. If Moderna and Oxford can successfully tailor their existing platforms to BDBV, it will validate the "plug-and-play" nature of these technologies, making it significantly easier to respond to future "Disease X" threats.
3. Strengthening Regional Health Infrastructure
The focus on the DRC and Uganda is not merely a matter of geography; it is an effort to bolster local public health infrastructure. Through these collaborations, CEPI is building a foundation for clinical trial networks in these regions. These networks will be invaluable not only for the current BDBV crisis but for future outbreaks of other emerging infectious diseases.
4. Navigating Political Volatility
The contrast between CEPI’s international investment and the U.S. government’s withdrawal from mRNA funding highlights a growing divide in how nations view public health security. While some governments are retracting support for long-term R&D, international coalitions are stepping in to fill the void. This shift suggests that the future of global health security will rely less on individual national budgets and more on collaborative, multinational funding mechanisms.
Conclusion
As the clinical trials for the IAVI, Moderna, and Oxford candidates begin to take shape, the world is watching closely. The BDBV outbreak serves as a stark reminder that even in an era of advanced biotechnology, humanity remains vulnerable to obscure, lethal viruses. However, the coordinated, multi-platform approach championed by CEPI offers a blueprint for a more resilient, proactive, and equitable global health future. The race is indeed on, and the outcome will be measured in lives saved and the strength of the systems we build to protect the most vulnerable populations on Earth.
About the Author
